Search

for
Search:

GlossaryLiraglutide (GLP-1 receptor agonist)

medication mimicking GLP-1 hormone to regulate blood sugar

Liraglutide is a medication that mimics a hormone called GLP-1 (glucagon-like peptide-1) to help regulate blood sugar levels and appetite. It is commonly used to treat type 2 diabetes under the brand name Victoza and for weight management under the brand name Saxenda.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 161 results

research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

59 citations, August 2021 in “Frontiers in Endocrinology”

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

From Evidence to Practice: Insights from the Multidisciplinary Team on the Optimal Integration of GLP-1 Receptor Agonists in Obesity Management Services

research From Evidence to Practice: Insights from the Multidisciplinary Team on the Optimal Integration of GLP-1 Receptor Agonists in Obesity Management Services

August 2024 in “Nutrition Bulletin”

GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.

research Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report

December 2024 in “Cureus”

Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.

research Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show

May 2024 in “Psychiatric News”

Weight-loss drugs are not linked to suicidal thoughts.

research Metabolic Syndrome: A New Definition and Management Guidelines

11 citations, December 2022 in “Arterial Hypertension”

New guidelines stress early diagnosis and lifestyle changes to manage metabolic syndrome and prevent complications.

View more "glp-1 receptor agonist" in research →

Community Join

5 / 5 results

community Female, 30, PCOS diagnosis, MPB Norwood 2. Endo refuses to give anything other than Spironolactone. Feel like I’m at my wit’s end here.

in Female 55 upvotes 1 year ago

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

community He used Dutasteride for 20 years. Interview

in Treatment 110 upvotes 2 months ago

Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.

community Wtf have we been doing for the last 30 years

in Treatment 548 upvotes 1 month ago

Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.

community What treatment helps diffuse hair thinning from insulin resistance?

in Treatment 1 upvotes 1 year ago

The individual is experiencing hair loss due to insulin resistance (IR) and is seeking advice. They are currently using a keto diet, supplements, exercise, and plan to add metformin to their regimen.

community Wouldn’t it be funny if there already was a drug that existed which reactivated sleeping follicles? It would be our own version of Ozempic

in Research/Science 204 upvotes 3 weeks ago

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.